Insider trading of Konstantinos Alataris, a President, CEO at ZSAN Zosano Pharma Corporation
Most recently Konstantinos Alataris exercised 127,389 shares worth $184,714.05 on 20 March 2017.
Zosano Pharma Corporation, a clinical stage pharmaceutical company, develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
- Zosano Pharma Corporation, 34790 Ardentech Court, Fremont 94555, United States